PR93389

HYDERABAD, India and NANJING, China, Dec. 1, 2021 /PRNewswire=KYODO JBN/ --

    Excelra, a leading global data & analytics provider, today announced its

partnership with Silexon AI Technology, a next-generation biotech company with

a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for

drug discovery and biopharmaceutical research.

    Under the agreement, Excelra will provide ADMET and Binding Assays datasets

from its GOSTAR database to Silexon. GOSTAR provides comprehensive information

encompassing over 8 million compounds and contains more than 28 million SAR

associated data points. The well-structured relational database can be utilized

for diverse applications across different phases of drug discovery and

development and aids in target validation, hit identification, early lead

Identification, and optimization.

    Silexon's AI/ML platform uses both high-quality, real-world biological data

and outstanding machine learning capabilities to aid in de novo drug design,

drug discovery, and biopharmaceutical research through its disruptive

predictive tools that help streamline the discovery and design process, thus

shortening the time to market for new life-saving drugs. Silexon focuses on

innovative biomedicines with unique target product profiles for undruggable,

difficult-to-drug, and novel targets in multiple therapeutic areas.

    Anandbir Singh Brar, CEO of Excelra, said, "We are excited that GOSTAR has

become the gold standard dataset for Biopharma and AI/ML companies. Our

partnership with Silexon underscores GOSTAR's ability to provide large,

normalized, quality-controlled datasets that empower a wide range of predictive

models. We are delighted to partner with Silexon and to be part of their

journey in developing the AI4D platform for drug discovery."

    Hainian ZENG, CEO of Silexon, said, "We look forward to combining the

well-annotated GOSTAR data with data accumulated and generated by Silexon's

proprietary AI/ML models and wet-lab experiments. Using our AI/ML platform, we

aim to address bottlenecks in drug discovery and biopharmaceutical research to

ultimately deliver innovative therapeutic candidates with higher overall

success rates. Our preliminary assessment gives us the confidence that GOSTAR's

database would be an important addition to our current training dataset for

next-generation modeling."

    About Silexon:

    Silexon is an emerging AI-empowered technology company that aims to create

an open AI platform for strategic collaboration to facilitate data-driven

biopharma research, empower drug R&D processes, and ultimately provide patients

with greater access to innovative drugs for their unmet medical needs. Silexon

stands for the integration of Silicon and Exon, and hence machine plus life. To

know more, visit http://www.silexon.tech/

    About Excelra:

    Excelra's data and analytics solutions empower innovation in life sciences

from molecule to market. The Excelra Edge comes from a seamless amalgamation of

proprietary data assets, domain expertise, and data sciences to accelerate drug

discovery and development.

    Excelra's Global Online Structure Activity Relationship Database (GOSTAR)

is the largest repository for structured SAR content. Available as a one-stop

data source, GOSTAR allows researchers to thoroughly explore the known chemical

space around a target of interest. The database is manually curated by

scientific teams who excerpt and enrich datasets from functional assays, in

vitro, and in vivo studies. A variety of small molecule activities encompassing

SAR, physicochemical, metabolic, ADME, and toxicological profiles are captured

in GOSTAR.

    To know more, visit: https://www.gostardb.com/

    Media Contact:

    Jigesh Shah – Director Marketing

    Email:  jigesh.shah@excelra.com

    Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg

    Source: Excelra Knowledge Solutions Pvt Ltd